



Medytox Inc.

www.medytox.com/?site_id=en

As the first botulinum toxin product developer in Korea, we feel pride and responsibility for this industry. Which is why we pursue to improve the transparency and the competitiveness of Korea's biopharmaceutical businesses by implementing of more scientific guidelines for industry practice.

Aiming to become a top global biopharmaceutical company. We plan to expand into the leading pharmaceutical markets and emerging markets. Ceaselessly conducting new research to introduce a new type of botulinum toxin product to the world market.

Main Products



CEO
Jung Hyun Ho

Location
78, Gangni 1-gil, Ochang-eup,
Cheongwon-gu, Cheongju-si,
Chungcheongbuk-do, Republic
of Korea

Specialty
Botulinum toxin products,
Medical aesthetics, Bio-phar-
maceuticals

Tel / Fax / E-mail
T. 82-2-6901-5880
F. 82-2-3476-8372

| Product | Ingredient | Characteristic |
|-----------|---|--|
| Neuronox® | Clostridium botulinum toxin type A (Hall strain) | - Representative brand of Medytox Inc. which is registered in 33 countries. - Neuronox® has ranked No.1 selling product in Korean market, and also in Japan, Thailand. |
| Innotox® | Clostridium botulinum toxin type A (Hall strain) | - The world's first liquid type botulinum toxin type A product. - Excluded the dilution process in using botulinum toxin product improving convenience of treatment and accuracy of dose. - Enhanced safety from excluding animal derivatives and HSA from the final product. |
| Coretox® | Clostridium botulinum toxin type A (150kDa) (Hall strain) | - An advanced new botulinum toxin type A product contains pure neurotoxin, excluding all non-toxin proteins from its ingredients. - Prevents users from gaining immunity by antibody formation which wear down the effects of botulinum toxin. - Enhanced safety from excluding animal derivatives and HSA from the final product. |

R&D Pipeline

| Division | Code | Indication | Stage |
|-----------------|-----------|--|---------------------|
| Biodrug | Neuronox® | Benign Masseteric Hypertrophy, Overactive Bladder, Migraine, Glabellar Line(US, EU, China, Taiwan, Russia), Lateral Canthal Line(US, EU), Blepharospasm(China) | Approved + clinical |
| | Innotox® | Aesthetic and Treatment (US, EU) | Approved + Clinical |
| | Coretox® | Upperlimb Spasticity | Approved + Clinical |
| | MT912 | Macular Degeneration | Preclinical |
| | MT927 | Immune Disorder | Discovery |
| | MT971 | Inflammatory Bowel Disease | Discovery |
| | MT981 | Solid cancers | Discovery |
| Synthetic Drugs | MT921 | Fat Reduction | Clinical |